AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Analysts have a consensus rating of "Hold" on AbCellera (5 analysts: 1 sell, 1 hold, 3 buy) with an average 1‑year target price of $7.75.
• AbCellera beat quarterly expectations—reported EPS of ($0.03) vs. ($0.18) est. and revenue of $44.85M vs. $6.31M est.—but remains unprofitable with a negative net margin (~198%) and analysts expect ~‑0.59 EPS for the year.
• Institutional interest is rising: HSBC boosted its stake by 375.4% and several firms (Virtu, Invesco, XTX, nVerses) added or initiated positions, with institutions/hedge funds owning about 61.42% of the stock.

AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $7.75.

Several equities analysts have recently issued reports on ABCL shares. Wall Street Zen upgraded shares of AbCellera Biologics from a "sell" rating to a "hold" rating in a report on Saturday, February 14th. Weiss Ratings restated a "sell (d-)" rating on shares of AbCellera Biologics in a report on Wednesday, January 21st.

Hedge Funds Weigh In On AbCellera Biologics

Several hedge funds have recently modified their holdings of the stock. Hsbc Holdings PLC increased its holdings in shares of AbCellera Biologics by 375.4% during the fourth quarter. Hsbc Holdings PLC now owns 117,031 shares of the company's stock valued at $401,000 after acquiring an additional 92,414 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of AbCellera Biologics during the fourth quarter valued at about $619,000. Invesco Ltd. increased its holdings in shares of AbCellera Biologics by 27.9% during the fourth quarter. Invesco Ltd. now owns 54,603 shares of the company's stock valued at $187,000 after acquiring an additional 11,914 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of AbCellera Biologics during the fourth quarter valued at about $1,242,000. Finally, nVerses Capital LLC acquired a new position in shares of AbCellera Biologics during the fourth quarter valued at about $121,000. Institutional investors and hedge funds own 61.42% of the company's stock.

AbCellera Biologics Stock Performance

ABCL stock opened at $3.43 on Thursday. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -7.00 and a beta of 0.85. The firm has a 50-day simple moving average of $3.38 and a two-hundred day simple moving average of $4.04. AbCellera Biologics has a one year low of $1.90 and a one year high of $6.51.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.15. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. The business had revenue of $44.85 million during the quarter, compared to analyst estimates of $6.31 million. As a group, equities analysts predict that AbCellera Biologics will post -0.59 earnings per share for the current fiscal year.

AbCellera Biologics Company Profile

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.